Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Search
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Respimat re-usable wins Pharmapack Eco-Design Award
The Respimat® re-usable inhaler device has won the 2020 Pharmapack Eco-Design Award. An enhanced version of the Respimat® soft mist inhaler, Respimat® re-usable has a lower environmental impact and is easy for patients to use.
Poultry
Poultry
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Boehringer Ingelheim announces appointments
Boehringer Ingelheim announces appointments
The impact of carbon reduction projects
Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Boehringer Ingelheim acquires Nerio Therapeutics
Today marks a significant step for Boehringer Ingelheim’s immuno-oncology pipeline by adding an innovative preclinical program with the acquisition of Nerio Therapeutics
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
History video
Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
ATM-Ranking-2021
Boehringer Ingelheim climbs two places. New early-stage research projects for disease areas relevant to low-to-middle income countries not reflected.
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.